Literature DB >> 27091219

A prospective study of Trichomonas vaginalis and prostate cancer risk among African American men.

Jay H Fowke1,2, Xijing Han3, J F Alderete4, Kelvin A Moses5, Lisa B Signorello6, William J Blot7,3.   

Abstract

BACKGROUND: African Americans (AA) have a higher prevalence of Trichomonas vaginalis (Tv) infection and a higher prostate (PC) risk. Past studies suggest an association between Tv seropositivity and PC, and therefore we prospectively investigated this association among AA men.
RESULTS: Incident PC cases were individually matched to controls in a nested case-control study within the Southern Community Cohort Study (SCCS). Primary analysis included 296 PC cases and 497 race-matched controls. Levels of Tv antibody response were measured by ELISA in serum collected at baseline. Tv antibody response did not significantly differ between cases and controls overall or within AA participants (253 AA cases). There were no significant associations or trends between levels of Tv response and PC risk or the diagnosis of aggressive PC.
CONCLUSION: We found no evidence of a prospective association between baseline Tv infection and PC risk in AA men. Tv infection in men may have substantial health implications in HIV transmission and reproductive outcomes, but may not impact future PC risk in AA men at high-risk for PC. Further efforts need to define past vs. present Tv infection and to separate pathophysiology from PC detection.

Entities:  

Keywords:  Prostate cancer; Race; Trichomonas vaginalis

Mesh:

Substances:

Year:  2016        PMID: 27091219      PMCID: PMC4835839          DOI: 10.1186/s13104-016-2033-3

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN: 1756-0500


Background

Trichomonas vaginalis (Tv) is a sexually transmitted protozoan parasite. In men, urethral infection may ascend to the prostatic urethra and glandular tissue. With asymptomatic infection common, Tv exposure may induce a sustained inflammatory response to advance prostate carcinogenesis [1]. Analysis of the Health Professionals Follow-up Study and the Physicians Health Study found that Tv antibody seropositivity was significantly associated with prostate cancer (PC) risk [2, 3] or PC death [2]. In contrast, Tv seropositivity was not associated with PC risk in the Prostate Cancer Prevention Trial (PCPT) [4] or a population-based case–control analysis [5]. The purpose of this study was to determine the prospective relationship between Tv infection and PC risk among African American (AA) men. Past studies included few AA men, although there are data suggesting the prevalence of Tv infection and the risk of PC may be greater than among white men [6].

Methods

Details of the Southern Community Cohort Study (SCCS) have been published [7]. Incident PC cases among nearly 35,000 male participants enrolled at age 40–79 during 2002–2009 were identified through linkages through 2013 with state tumor registries and the National Death Index. All participants provided written informed consent, and all protocols were approved by Institutional Review Boards at Vanderbilt University and Meharry Medical College. All SCCS data can be requested through an online request (southerncommunitystudy.org). The request will be reviewed by the SCCS Data and Biospecimen Use Committee to ensure that it is scientifically justified and that participant confidentiality is preserved. Two controls per case were selected by incidence density sampling and were individually matched by age (5 years), race (self-reported black or white), site, and time of donation of blood samples at study entry. A blood sample was collected at baseline recruitment, and serum was frozen-stored at −80 °C. Serum was assayed in duplicate for antibodies against Tv by ELISA to detect the IgG antibodies against the purified recombinant Tv α-actinin protein and assessed spectrophotometrically [8]. We previously assigned scores from 0 to 4+ to serum based on the calculation of P/N values obtained using the protein ACT-P2 as the target [2–4, 8]. For this study, cutoff points for seropositivity were obtained by dividing the average OD405nm of the seropositive control serum by the corresponding seronegative control serum. The lowest seronegative control was assigned a score of 0 (zero). Values from 0 to the next lowest was given a score of 1+, and subsequent scores of 2+, 3+, and 4+ were assigned similarly as values increased. The sera with P/N scores ≤2 were negative as evidenced by lack of detection of any T. vaginalis proteins by immunoblot [8]. Scores ≥3 were positive and had antibody to α-actinin and other trichomonad proteins [8]. We used conditional logistic regression to compute odds ratios (OR) and 95 % confidence intervals while controlling for household income. Cancer stage or Gleason score from state tumor registries providing these data were also analyzed after controlling for age, race, and income.

Results

The majority of the study population was over 60 years of age at recruitment (n = 549, 62 %), and reported a household income less than $15,000/year (n = 512, 58 %). Approximately 85 % of the study population was AA. Table 1 summarizes the association between Tv seropositive status and PC. Mean antibody response levels were similar between cases and controls (all p > 0.05). There was no significant association between Tv and PC in the total study population, or when restricting to AA men. Furthermore, Tv exposure was not associated with PC Gleason score of 7 or more, or stage 2–4 PC at diagnosis, in a case-only analysis (Table 2).
Table 1

Trichomonas vaginalis and association with prostate cancer risk

T. vaginalis CasesControlsOR95 % CI
n296585
Mean (SD)0.26 (0.11)0.26 (0.11)
Serostatus
 Negative227 (76.7 %)461 (78.8 %)1.0Ref
 Positive69 (23.3 %)124 (21.2 %)1.110.77–1.61
Score
  060 (20.3 %)132 (22.6 %)1.0Ref
  195 (32.1 %)168 (28.7 %)1.180.77, 1.82
  272 (24.3 %)161 (27.5 %)0.940.58–1.53
  350 (16.9 %)84 (14.4 %)1.250.74–2.11
  4+19 (6.4 %)40 (6.8 %)0.980.48–1.97
African Americans Onlya
n253497
Mean (SD)0.26 (0.11)0.26 (0.11)
Serostatus
 Neg191 (75.5 %)386 (77.7 %)1.0Ref
 Pos62 (24.5 %)111 (22.3 %)1.120.76–1.66
Score
 050 (19.8 %)104 (20.9 %)1.0Ref
 180 (31.6 %)145 (29.2 %)1.100.69–1.76
 261 (24.1 %)137 (27.6 %)0.870.51–1.47
 344 (17.4 %)74 (14.9 %)1.180.67–2.08
 4+18 (7.1 %)37 (7.4 %)0.950.45–1.97

Adjusted for age at diagnosis, race, income

aAdjusted for age at diagnosis and income*

Table 2

Trichomonas vaginalis seropositive status and diagnosis of aggressive prostate cancer

Diagnosis of aggressive PCa
Gleason < 7Gleason ≥ 7OR95 % CI
n74101
Mean (SD)0.25 (0.10)0.26 (0.10)
Serostatus
 Negative60 (81.1 %)80 (79.2 %)
 Positive14 (18.9 %)21 (20.8 %)1.040.48–2.26

Stage and grade data were not provided by every tumor registry

aAdjusted for age at diagnosis, race, and income

Trichomonas vaginalis and association with prostate cancer risk Adjusted for age at diagnosis, race, income aAdjusted for age at diagnosis and income* Trichomonas vaginalis seropositive status and diagnosis of aggressive prostate cancer Stage and grade data were not provided by every tumor registry aAdjusted for age at diagnosis, race, and income

Discussion

Tv disproportionately affects minorities and low-income populations [6]. However, unlike two past studies of predominately white professionals [2, 3], we found no evidence of association within AA men. A post hoc power calculation based on a similar matched nested case–control design and assuming a 25 % exposure, Type I error of 5 %, and 80 % power, would be able to detect an OR = 1.42, suggesting a sufficient sample size to identify a moderate association. Residual confounding is unlikely to have led to a null association. As previously detailed, differences in patient characteristics and detection protocols could explain differences in results across studies [4]. Similarly, an inflammatory effect from Tv would likely increase PSA levels, and thus increase the likelihood of detecting an asymptomatic PC and lead to a positive association. No association between Tv seropositivity and PC was found in the PCPT, with rigorous control for PC screening including an end of study prostate biopsy [4]. Alternatively, analysis of the Prostate, Lung, Colorectal and Ovarian cancer screening trial found Tv seropositivity significantly associated with benign prostatic hyperplasia [9], suggesting Tv may exacerbate lower urinary tract symptom severity and possibly lead to a PC detection. [10] Tv seropositivity is relatively stable over time [10], limiting the ability to identify an etiologically relevant time of exposure. Our prospective analysis found no association between baseline Tv seropositivity and future PC risk, and further efforts are needed to define past vs. recent Tv infection and to separate pathophysiology from the detection of PC.
  10 in total

1.  The prevalence of trichomoniasis in young adults in the United States.

Authors:  William C Miller; Heidi Swygard; Marcia M Hobbs; Carol A Ford; Mark S Handcock; Martina Morris; John L Schmitz; Myron S Cohen; Kathleen Mullan Harris; J Richard Udry
Journal:  Sex Transm Dis       Date:  2005-10       Impact factor: 2.830

2.  Southern community cohort study: establishing a cohort to investigate health disparities.

Authors:  Lisa B Signorello; Margaret K Hargreaves; Mark D Steinwandel; Wei Zheng; Qiuyin Cai; David G Schlundt; Maciej S Buchowski; Carolyne W Arnold; Joseph K McLaughlin; William J Blot
Journal:  J Natl Med Assoc       Date:  2005-07       Impact factor: 1.798

3.  Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer.

Authors:  Siobhan Sutcliffe; Edward Giovannucci; John F Alderete; Te-Hung Chang; Charlotte A Gaydos; Jonathan M Zenilman; Angelo M De Marzo; Walter C Willett; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-05       Impact factor: 4.254

4.  Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors:  Benjamin N Breyer; Wen-Yi Huang; Charles S Rabkin; John F Alderete; Ratna Pakpahan; Tracey S Beason; Stacey A Kenfield; Jerome Mabie; Lawrence Ragard; Kathleen Y Wolin; Robert L Grubb; Gerald L Andriole; Siobhan Sutcliffe
Journal:  BJU Int       Date:  2015-04-23       Impact factor: 5.588

5.  Epitopes of the highly immunogenic Trichomonas vaginalis α-actinin are serodiagnostic targets for both women and men.

Authors:  Calvin J Neace; J F Alderete
Journal:  J Clin Microbiol       Date:  2013-04-24       Impact factor: 5.948

6.  Persistence of Trichomonas vaginalis serostatus in men over time.

Authors:  Siobhan Sutcliffe; John F Alderete; Calvin Neace; Patrick A Joyce; Charlotte A Gaydos; James I A Huth; Lorelei A Mucci; Lisa B Signorello
Journal:  Cancer Causes Control       Date:  2015-07-30       Impact factor: 2.506

7.  Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial.

Authors:  Siobhan Sutcliffe; John F Alderete; Cathee Till; Phyllis J Goodman; Ann W Hsing; Jonathan M Zenilman; Angelo M De Marzo; Elizabeth A Platz
Journal:  Int J Cancer       Date:  2009-05-01       Impact factor: 7.396

8.  Trichomonas vaginalis infection and risk of advanced prostate cancer.

Authors:  Irene M Shui; Suzanne Kolb; Christi Hanson; Siobhan Sutcliffe; Jennifer R Rider; Janet L Stanford
Journal:  Prostate       Date:  2016-01-28       Impact factor: 4.104

9.  Prospective study of effect modification by Toll-like receptor 4 variation on the association between Trichomonas vaginalis serostatus and prostate cancer.

Authors:  Yen Ching Chen; Yi Ling Huang; Elizabeth A Platz; John F Alderete; Lu Zheng; Jennifer R Rider; Peter Kraft; Edward Giovannucci; Siobhan Sutcliffe
Journal:  Cancer Causes Control       Date:  2012-11-21       Impact factor: 2.506

10.  Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study.

Authors:  Jennifer R Stark; Gregory Judson; John F Alderete; Vasanthakrishna Mundodi; Ashwini S Kucknoor; Edward L Giovannucci; Elizabeth A Platz; Siobhan Sutcliffe; Katja Fall; Tobias Kurth; Jing Ma; Meir J Stampfer; Lorelei A Mucci
Journal:  J Natl Cancer Inst       Date:  2009-09-09       Impact factor: 13.506

  10 in total
  7 in total

1.  Trichomonas vaginalis infection and risk of prostate cancer: associations by disease aggressiveness and race/ethnicity in the PLCO Trial.

Authors:  Miguelle Marous; Wen-Yi Huang; Charles S Rabkin; Richard B Hayes; John F Alderete; Bernard Rosner; Robert L Grubb; Anke C Winter; Siobhan Sutcliffe
Journal:  Cancer Causes Control       Date:  2017-07-01       Impact factor: 2.506

Review 2.  Multiple pathogens and prostate cancer.

Authors:  James S Lawson; Wendy K Glenn
Journal:  Infect Agent Cancer       Date:  2022-05-30       Impact factor: 3.698

3.  Association between Trichomonas vaginalis and prostate cancer mortality.

Authors:  Sabrina H Tsang; Samuel F Peisch; Brendan Rowan; Sarah C Markt; Amparo G Gonzalez-Feliciano; Siobhan Sutcliffe; Elizabeth A Platz; Lorelei A Mucci; Ericka M Ebot
Journal:  Int J Cancer       Date:  2018-12-04       Impact factor: 7.396

4.  Prevalence and the evaluation of culture, wet mount, and ELISA methods for the diagnosis of Trichomonas vaginalis infection among Ghanaian women using urine and vaginal specimens.

Authors:  Collins Adjei; Richard Boateng; Albert Dompreh; Bismark Okyere; Eddie-Williams Owiredu
Journal:  Trop Med Health       Date:  2019-05-16

5.  Molecular Examination of Trichomonas vaginalis Infection and Risk of Prostate Cancer in the Biopsy of Patients with Different Prostate Lesions.

Authors:  Zeinab Kamarkhani; Raheleh Rafiei-Sefiddashti; Leila Haghighi; Alireza Badirzadeh; Ramtin Hadighi
Journal:  Ethiop J Health Sci       Date:  2021-03

6.  Prevalence of Trichomonas vaginalis infection and protozoan load in South African women: a cross-sectional study.

Authors:  Dewi J de Waaij; Jan Henk Dubbink; Sander Ouburg; Remco P H Peters; Servaas A Morré
Journal:  BMJ Open       Date:  2017-10-08       Impact factor: 2.692

Review 7.  Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention.

Authors:  Lanshan Huang; Melissa J LaBonte; Stephanie G Craig; Stephen P Finn; Emma H Allott
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.